John Myers - Rentokil Initial Managing Director
RKLIF Stock | USD 5.45 0.75 15.96% |
Managing Director
Mr. John Myers is Managing Director, North America of Rentokil Initial PLC. John joined Rentokil Initial in 2008 as President and Chief Executive of the Pest Control division in North America. Previously John served as Vice President of Business Development, Group VP, VP of Business Strategy and as Senior VP of Sales at Cintas Corporationrationration. Prior to that, he was President and Chief Executive at Bio Quest LLC. John has a diverse business background, with extensive sales, marketing and business strategy experience. He is a graduate of the University of Vermont where he earned a Bachelors degree in Business Administration. Additionally, he earned an MBA from Mercer University in Atlanta. since 2013.
Age | 65 |
Tenure | 11 years |
Professional Marks | MBA |
Phone | 44 12 9385 8000 |
Web | https://www.rentokil-initial.com |
Rentokil Initial Management Efficiency
The company has return on total asset (ROA) of 0.0419 % which means that it generated a profit of $0.0419 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2084 %, meaning that it generated $0.2084 on every $100 dollars invested by stockholders. Rentokil Initial's management efficiency ratios could be used to measure how well Rentokil Initial manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 1 records | MANAGING DIRECTOR Age | ||
Karl Werner | RB Global | 59 |
Management Performance
Return On Equity | 0.21 | |||
Return On Asset | 0.0419 |
Rentokil Initial Plc Leadership Team
Elected by the shareholders, the Rentokil Initial's board of directors comprises two types of representatives: Rentokil Initial inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rentokil. The board's role is to monitor Rentokil Initial's management team and ensure that shareholders' interests are well served. Rentokil Initial's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rentokil Initial's outside directors are responsible for providing unbiased perspectives on the board's policies.
Stewart Power, Chief Marketing Officer | ||
Alain Moffroid, Managing Director, Pacific | ||
Julie Southern, Non-Executive Director | ||
Richard Solomons, Non-Executive Director | ||
Mark Purcell, Chief Officer | ||
Vanessa Evans, Group Human Resources Director | ||
Alan Giles, Independent Non-Executive Director | ||
Phill Wood, Managing Director | ||
Martin Sawkins, Group HR Director | ||
Angela SeymourJackson, Non-Executive Director | ||
Crispin Davis, Non-Executive Director | ||
Malcolm Padley, Director Communications | ||
Linda Yueh, Non-Executive Director | ||
Gary Booker, Chief Marketing, Innovation and Strategy Officer | ||
Daragh Fagan, Group General Counsel, Company Secretary and Member of Investment Committee | ||
John Pettigrew, Non-Executive Director | ||
Katharine Rycroft, Head of Investor Relations | ||
Jurgen Hofling, Managing Director, Europe | ||
Peter Bamford, Independent Non-Executive Director | ||
Andrew Ransom, CEO, Executive Director and Chairman of Investment Committee | ||
Jeremy Townsend, CFO, CIO, Executive Director, Chairman of Disclosure Committee, Chairman of Group Risk Committee and Member of Investment Committee | ||
Christopher Geoghegan, Non-Executive Director | ||
Andy Ransom, CEO, Executive Director | ||
Stuart IngallTombs, CFO Director | ||
John McAdam, Non-Executive Chairman of the Board | ||
John Myers, Managing Director | ||
Paul Cochrane, Managing Director, Asia | ||
Rachel Canham, Group Counsel | ||
Richard Burrows, Independent Non-Executive Director |
Rentokil Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Rentokil Initial a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.21 | |||
Return On Asset | 0.0419 | |||
Profit Margin | 0.09 % | |||
Operating Margin | 0.13 % | |||
Current Valuation | 18.1 B | |||
Shares Outstanding | 2.52 B | |||
Shares Owned By Insiders | 0.69 % | |||
Shares Owned By Institutions | 75.84 % | |||
Price To Earning | 38.36 X | |||
Price To Book | 9.36 X |
Currently Active Assets on Macroaxis
When determining whether Rentokil Initial Plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rentokil Initial's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rentokil Initial Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rentokil Initial Plc Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rentokil Initial Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Rentokil Pink Sheet analysis
When running Rentokil Initial's price analysis, check to measure Rentokil Initial's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rentokil Initial is operating at the current time. Most of Rentokil Initial's value examination focuses on studying past and present price action to predict the probability of Rentokil Initial's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rentokil Initial's price. Additionally, you may evaluate how the addition of Rentokil Initial to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |